- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures | 1 | GlobeNewswire (USA) | ||
| 06.11. | Rapport Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.09. | Truist Securities initiates Rapport Therapeutics stock with Buy rating | 5 | Investing.com | ||
| 11.09. | Rapport Therapeutics, Inc.: Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | 1 | GlobeNewswire (USA) | ||
| 10.09. | Rapport Therapeutics prices $250M stock at $26 per share | 2 | Seeking Alpha | ||
| RAPPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.09. | Rapport Therapeutics prices $250 million public offering at $26 per share | 2 | Investing.com | ||
| 10.09. | Rapport Therapeutics, Inc.: Rapport Announces Pricing of Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.09. | Rapport Therapeutics launches $250 million public stock offering | 15 | Investing.com | ||
| 08.09. | Rapport Therapeutics, Inc.: Rapport Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.09. | Rapport Therapeutics: Stifel hebt Kursziel nach Studienerfolg deutlich auf 56 $ an | 2 | Investing.com Deutsch | ||
| 08.09. | Stifel raises Rapport Therapeutics stock price target to $56 on positive trial data | 2 | Investing.com | ||
| 08.09. | Rapport Therapeutics Stock Rises To 117% After Positive Phase 2a Trial Results | 3 | RTTNews | ||
| 08.09. | TD Cowen bestätigt Kaufempfehlung für Rapport Therapeutics nach starken Studiendaten | 3 | Investing.com Deutsch | ||
| 08.09. | Rapport Therapeutics stock rating reiterated as Buy by TD Cowen | 16 | Investing.com | ||
| 08.09. | Rapport Therapeutics stock soars after positive Phase 2a seizure drug results | 13 | Investing.com | ||
| 08.09. | Rapport Therapeutics: Aktie springt nach positiven Phase-2a-Studienergebnissen um 160 % | 2 | Investing.com Deutsch | ||
| 08.09. | Rapport Therapeutics: Phase 2a Trial Of RAP-219 Meets Primary Endpoint | 1 | RTTNews | ||
| 08.09. | Rapport Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 08.09. | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | 356 | GlobeNewswire (Europe) | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,454 | -2,57 % | Analyse und Ausblick: Evotec | ||
| PALATIN TECHNOLOGIES | 22,310 | +1,09 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,235 | +0,38 % | Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics | ||
| ABIVAX | 97,70 | 0,00 % | EQS-News: ABIVAX: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis | EQS-News: ABIVAX
/ Key word(s): Study results
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant... ► Artikel lesen | |
| GERON | 1,105 | -2,17 % | Geron Corporation Announces Executive Leadership Transitions and Appointments | FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| GALAPAGOS NV | 27,140 | -0,59 % | Galapagos NV: Galapagos Receives Transparency Notifications from Bank of America | Mechelen, Belgium; November 26, 2025, 07:30 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.
Pursuant to Belgian... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,790 | -0,26 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific... ► Artikel lesen | |
| VIDAC PHARMA | 0,552 | 0,00 % | Die demografische Uhr tickt: So positionieren sich Bayer, Vidac Pharma und Novo Nordisk im Milliarden-Kampf um unsere Gesundheit | Die demografische Uhr tickt unaufhaltsam. Eine alternde Gesellschaft bringt eine Flut von Volkskrankheiten wie Herzleiden, Krebs und Diabetes mit sich. Jede einzelne ein Milliardenmarkt, der die Gesundheitssysteme... ► Artikel lesen | |
| CYTOKINETICS | 57,00 | +0,88 % | Cytokinetics, Incorporated: Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 | Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers SOUTH SAN FRANCISCO, Calif., Nov.... ► Artikel lesen | |
| PALISADE BIO | 1,800 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development | Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025... ► Artikel lesen | |
| FIBROGEN | 7,100 | -1,39 % | FibroGen, Inc.: FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit | ||
| CYBIN | 5,250 | +1,94 % | Cybin Inc.: Cybin to Participate in the Jefferies Global Healthcare Conference in London | Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,972 | +1,34 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 3,100 | +12,32 % | Minerva Neurosciences, Inc: Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors | BURLINGTON, Mass., Nov. 19, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment... ► Artikel lesen | |
| ROIVANT SCIENCES | 18,230 | +1,19 % | Roivant Sciences: Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) | Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including... ► Artikel lesen |
Das Unternehmen RAPPORT THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 29,500 Euro und damit +2,79 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPPORT THERAPEUTICS INC finden Sie auf Wallstreet Online.